Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant Schizophrenia
Ravi Anand, Alessio Turolla, Giovanni Chinellato, et al.
The International Journal of Neuropsychopharmacology (2023) Vol. 26, Iss. 8, pp. 523-528
Open Access | Times Cited: 11

Showing 11 citing articles:

The schizophrenia syndrome, circa 2024: What we know and how that informs its nature
Rajiv Tandon, Henry A. Nasrallah, Schahram Akbarian, et al.
Schizophrenia Research (2023) Vol. 264, pp. 1-28
Open Access | Times Cited: 57
Overview of Novel Antipsychotic Drugs: State of the Art, New Mechanisms, and Clinical Aspects of Promising Compounds
Letizia Biso, Marco Carli, Marco Scarselli, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 85-85
Open Access | Times Cited: 1
New Drug Treatments for Schizophrenia: A Review of Approaches to Target Circuit Dysfunction
Oliver Howes, Eleanor Dawkins, Maria Lobo, et al.
Biological Psychiatry (2024) Vol. 96, Iss. 8, pp. 638-650
Open Access | Times Cited: 14
Novel Compounds in the Treatment of Schizophrenia—A Selective Review
Eva-Maria Tsapakis, Kalliopi Diakaki, Apostolos Miliaras, et al.
Brain Sciences (2023) Vol. 13, Iss. 8, pp. 1193-1193
Open Access | Times Cited: 17
Evenamide: A Potential Pharmacotherapeutic Alternative for Treatment-Resistant Schizophrenia
Raghunath Singh, Margaret Hahn, Yashika Bansal, et al.
The International Journal of Neuropsychopharmacology (2024) Vol. 27, Iss. 2
Open Access | Times Cited: 5
Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape
Preetika Govil, Joshua T. Kantrowitz
CNS Drugs (2025)
Closed Access
IUPHAR Review - Novel therapeutic targets for schizophrenia treatment: a translational perspective
Veronica Begni, Alessia Marchesin, Marco Andrea Riva
Pharmacological Research (2025), pp. 107690-107690
Open Access
Insights into the Mechanism of Action of Antipsychotic Drugs Derived from Animal Models: Standard of Care versus Novel Targets
Anthony A. Grace, Daniela L. Uliana
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12374-12374
Open Access | Times Cited: 11
Current emerging therapeutic targets and clinical investigational agents for schizophrenia: Challenges and opportunities
Na Ye, Qi Wang, Yue Li, et al.
Medicinal Research Reviews (2024)
Closed Access | Times Cited: 2
Insights into the Mechanism of Action of Antipsychotic Drugs Derived from Animal Models: Standard of Care versus Novel Targets
Anthony A. Grace, Daniela Uliana
(2023)
Open Access | Times Cited: 3
Efficacy and safety of evenamide, a glutamate modulator, added to a second-generation antipsychotic in inadequately/poorly responding patients with chronic schizophrenia: results from a randomized, double-blind, placebo-controlled, phase 3, international clinical trial
Ravi Anand, Alessio Turolla, Giovanni Chinellato, et al.
Neuropharmacology (2024), pp. 110275-110275
Open Access
Page 1

Scroll to top